Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis.
Watanabe R, Ishii T, Araki K, Ishizuka M, Kamogawa Y, Fujita Y, Shirota Y, Fujii H, Harigae H. Watanabe R, et al. Among authors: ishii t. Mod Rheumatol. 2016;26(3):465-6. doi: 10.3109/14397595.2015.1012797. Epub 2015 Jun 29. Mod Rheumatol. 2016. PMID: 25698368 No abstract available.
A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S; SHINOBI study group. Ogata A, et al. Among authors: ishii t. Mod Rheumatol. 2018 Jan;28(1):76-84. doi: 10.1080/14397595.2017.1332507. Epub 2017 Jun 16. Mod Rheumatol. 2018. PMID: 28622048 Free article. Clinical Trial.
Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus.
Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Fujii H, Shirota Y, Shirai T, Fujita Y, Watanabe R, Chiu SW, Yamaguchi T, Harigae H. Ishii T, et al. Mod Rheumatol. 2018 Nov;28(6):986-992. doi: 10.1080/14397595.2018.1432331. Epub 2018 Feb 15. Mod Rheumatol. 2018. PMID: 29363990 Clinical Trial.
Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S, Yamakawa R; SHINOBI Study Group. Ogata A, et al. Among authors: ishii t. Mod Rheumatol. 2019 Sep;29(5):767-774. doi: 10.1080/14397595.2018.1533514. Epub 2018 Dec 14. Mod Rheumatol. 2019. PMID: 30299202 Free article. Clinical Trial.
Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
Tanaka Y, Takeuchi T, Okada M, Ishii T, Nakajima H, Kawai S, Nagashima T, Hayashi N, Wang L, Tummala R. Tanaka Y, et al. Among authors: ishii t. Mod Rheumatol. 2020 Jan;30(1):101-108. doi: 10.1080/14397595.2019.1583833. Epub 2019 Mar 21. Mod Rheumatol. 2020. PMID: 30793642 Free article. Clinical Trial.
4,491 results